KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Short term Debt (2016 - 2025)

Sarepta Therapeutics has reported Short term Debt over the past 12 years, most recently at $36.0 million for Q3 2025.

  • For Q3 2025, Short term Debt fell 60.7% year-over-year to $36.0 million; the TTM value through Sep 2025 reached $36.0 million, down 60.7%, while the annual FY2023 figure was $105.5 million, N/A changed from the prior year.
  • Short term Debt for Q3 2025 was $36.0 million at Sarepta Therapeutics, down from $91.6 million in the prior quarter.
  • Over five years, Short term Debt peaked at $105.6 million in Q1 2024 and troughed at $36.0 million in Q3 2025.
  • A 3-year average of $86.0 million and a median of $91.6 million in 2024 define the central range for Short term Debt.
  • On a YoY basis, Short term Debt climbed as much as 60.7% in 2025 and fell as far as 60.7% in 2025.
  • Year by year, Short term Debt stood at $105.5 million in 2023, then decreased by 13.17% to $91.6 million in 2024, then plummeted by 60.7% to $36.0 million in 2025.
  • Business Quant data shows Short term Debt for SRPT at $36.0 million in Q3 2025, $91.6 million in Q3 2024, and $91.5 million in Q2 2024.